{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T05:45:23Z","timestamp":1785908723879,"version":"3.56.0"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The clinical efficacy of neoadjuvant immunotherapy combined with chemotherapy (NICT) in patients with locally advanced gastric cancer (LAGC) exhibits considerable variability. In this study, we developed and validated a radiomics-based scoring system to inform personalized neoadjuvant therapy strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on a multicenter cohort comprising 633 LAGC patients who underwent neoadjuvant therapy between 2019 and 2023. The primary endpoint was major pathological response (MPR). Radiomic features were extracted and selected from contrast-enhanced CT images obtained before neoadjuvant therapy to construct a radiomics scoring system, which stratified patients into high-, intermediate-, and low-score groups. The therapeutic outcomes across different groups were compared to discern patients who are likely to benefit from NICT as opposed to those who would derive more benefit from neoadjuvant chemotherapy alone (NACT). Additionally, analysis of tumor microenvironment immune infiltration and functional enrichment were performed to explore the potential biological mechanisms underlying the radiomic signatures.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the intermediate-score group, the MPR rates were significantly higher among patients receiving NICT compared to those receiving NACT (training set: 49.2% vs. 26.0%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.005; validation set: 51.6% vs. 19.2%,\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.002). In contrast, no significant differences were observed in the high- or low-score groups. The analysis of immune infiltration indicated that the intermediate-score group exhibited significantly higher baseline levels of mast cells and dendritic cells compared to the combined high- and low-score groups (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05). Post-treatment evaluation following NICT revealed a significant increase in CD8+ T-cell infiltration relative to baseline levels within the intermediate-score group (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0=\u00a00.033). The gene KRT5 was identified as differentially expressed and correlated with dendritic cell abundance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The radiomics scoring system exhibits potential for stratifying patients who may be appropriate candidates for NICT or for whom the de-escalation of immunotherapy might be considered in future prospective studies, thereby contributing to the optimization of neoadjuvant treatment strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1848969","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:53:03Z","timestamp":1785905583000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing patient selection for neoadjuvant immunotherapy in gastric cancer via pre-treatment imaging analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Hao-Xiang","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Ning","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiu-Xian","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai-Ming","family":"Weng","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Fan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Wei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Quan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Yue","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping-","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hui","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Ming","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Chongqing Key Laboratory of Digestive Malignancies, Daping Hospital, Army Medical University (Third Military Medical University)","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Sheng","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University","place":["Zhangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Xian","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Wei","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Gastric Surgery, Fujian Medical University Union Hospital","place":["Fuzhou, China"]},{"name":"Key Laboratory of Ministry of Education of Gastrointestinal Cancer, Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70473-5","article-title":"Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial","volume":"15","author":"Noh","year":"2014","journal-title":"Lancet Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.36.5908","article-title":"Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer","volume":"29","author":"Sasako","year":"2011","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/nejmoa055531","article-title":"Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer","volume":"355","author":"Cunningham","year":"2006","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00676-4","article-title":"Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): final report of a randomised, open-label, phase 3 trial","volume":"26","author":"Zhang","year":"2025","journal-title":"Lancet Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-44309-5","article-title":"Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial","volume":"15","author":"Lin","year":"2024","journal-title":"Nat Commun"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01654-3","article-title":"Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial","volume":"400","author":"Livingstone","year":"2022","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00692-6","article-title":"Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Kang","year":"2022","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"38","DOI":"10.7326\/aitc202402200","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10120-019-00999-9","article-title":"Prognostic impacts of the combined positive score and the tumor proportion score for programmed death ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer","volume":"23","author":"Yamashita","year":"2020","journal-title":"Gastric Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/sla.0000000000002410","article-title":"The dynamic and transient immune microenvironment in locally advanced esophageal adenocarcinoma post chemoradiation","volume":"268","author":"Kelly","year":"2018","journal-title":"Ann Surg"},{"key":"B15","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-020-01273-0","article-title":"Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections","volume":"20","author":"Ye","year":"2020","journal-title":"Cancer Cell Int"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01601","article-title":"First-line nivolumab plus chemotherapy for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 3-year follow-up of the phase III CheckMate 649 trial","volume":"42","author":"Janjigian","year":"2024","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1172\/jci175834","article-title":"Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer","volume":"134","author":"Sun","year":"2024","journal-title":"J Clin Invest"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.11.036","article-title":"Radiomics: extracting more information from medical images using advanced feature analysis","volume":"48","author":"Lambin","year":"2012","journal-title":"Eur J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106992","article-title":"Non-linear modifications enhance prediction of pathological response to pre-operative PD-1 blockade in lung cancer: A longitudinal hybrid radiological model","volume":"198","author":"Jin","year":"2023","journal-title":"Pharmacol Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2020.109205","article-title":"Radiomic signature-based nomogram to predict disease-free survival in stage II and III colon cancer","volume":"131","author":"Yao","year":"2020","journal-title":"Eur J Radiol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102805","article-title":"A transformer-based deep learning model for early prediction of lymph node metastasis in locally advanced gastric cancer after neoadjuvant chemotherapy using pretreatment CT images","volume":"75","author":"Zheng","year":"2024","journal-title":"EClinicalMedicine"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002184","article-title":"Predicting early recurrence in locally advanced gastric cancer after gastrectomy using CT-based deep learning model: a multicenter study","volume":"111","author":"Guo","year":"2025","journal-title":"Int J Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s11547-023-01617-6","article-title":"Delta computed tomography radiomics features-based nomogram predicts long-term efficacy after neoadjuvant chemotherapy in advanced gastric cancer","volume":"128","author":"Shen","year":"2023","journal-title":"Radiol Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12967-025-06363-z","article-title":"Multi-cohort study in gastric cancer to develop CT-based radiomic models to predict pathological response to neoadjuvant immunotherapy","volume":"23","author":"Huang","year":"2025","journal-title":"J Transl Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-7493-1_12","article-title":"Profiling tumor infiltrating immune cells with CIBERSORT","volume":"1711","author":"Chen","year":"2018","journal-title":"Methods Mol Biol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(20)30271-0","article-title":"Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial","volume":"21","author":"Kawazoe","year":"2020","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00358-3","article-title":"First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: a single-arm, single-centre, phase 2 trial","volume":"24","author":"Cytryn","year":"2023","journal-title":"Lancet Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.00795","article-title":"Pathologic response of phase III study: perioperative camrelizumab plus rivoceranib and chemotherapy versus chemotherapy for locally advanced gastric cancer (DRAGON IV\/CAP 05)","volume":"43","author":"Li","year":"2025","journal-title":"J Clin Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02758-x","article-title":"Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial","volume":"30","author":"Verschoor","year":"2024","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508433","article-title":"Three-year follow-up of neoadjuvant tislelizumab with chemotherapy in locally advanced gastric and gastroesophageal junction adenocarcinoma: revealing cancer-associated fibroblast heterogeneity corresponding to PD-1 blockade efficacy","volume":"13","author":"Lin","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41392-023-01658-3","article-title":"Tumor-repopulating cell-derived microparticles elicit cascade amplification of chemotherapy-induced antitumor immunity to boost anti-PD-1 therapy","volume":"8","author":"Bie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.ccell.2025.07.014","article-title":"DNASE1L3-expressing dendritic cells promote CD8(+) T cell function and anti-PD-(L)1 therapy efficacy by degrading neutrophil extracellular traps","volume":"43","author":"Chen","year":"2025","journal-title":"Cancer Cell"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav7431","article-title":"Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy","volume":"12","author":"Mayoux","year":"2020","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2024.11.011","article-title":"Cytokines in cancer","volume":"43","author":"Kureshi","year":"2025","journal-title":"Cancer Cell"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00789-4","article-title":"Antigen presentation in cancer - mechanisms and clinical implications for immunotherapy","volume":"20","author":"Yang","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02192-w","article-title":"CARD11 signaling regulates CD8(+) T cell tumoricidal function","volume":"26","author":"Hu","year":"2025","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848969\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T04:53:08Z","timestamp":1785905588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1848969\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":40,"alternative-id":["10.3389\/fimmu.2026.1848969"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1848969","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"article-number":"1848969"}}